ARCHIVES

Chop Analysis Shows Program Had Major Impact In Communities

This article is from The Cancer Letter archive.

Vol. 11 No. 04 | January 25, 1985

Download PDF Visit The Full Archive

Related Articles

FDA Approves Bexxar For Non-Hodgkin’s Lymphoma

June 27, 2003

Inhibitor Reduces Spleen Size By 35 Percent or More in Phase III

June 28, 2013

Reviewers Find I-ELCAP Is A Trial That Never Ends, With 90 Percent of Consent Forms Unobtainable

April 29, 2011

Funding Opportunities.

April 19, 2002

Cancer Advocates Ask House By Byspass Budget; NCCR’s Day Calls For $380 Mil. Minimum Increase

March 12, 1993

Phase III Trial Fails to Extend OS After Meeting Primary Endpoint Of Durable Response Rate

April 25, 2014